Advertisement


Fredrick B. Hagemeister, Jr, MD, on Using Rituximab Maintenance

2016 Pan Pacific Lymphoma Conference

Advertisement

Fredrick B. Hagemeister, Jr, MD, of the University of Texas MD Anderson Cancer Center, discusses whether rituximab maintenance should be used in indolent lymphomas other than follicular.



Related Videos

Lymphoma

Jonathan W. Friedberg, MD: Marginal Zone Lymphoma Therapy Update

Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses the use of rituximab as a single agent and in combination with chemotherapy, the emerging role of n...

Lymphoma

Bruce D. Cheson, MD, and Julie M. Vose, MD, MBA, on Staging Lymphoma

Bruce D. Cheson, MD, of Georgetown University Hospital, and Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discuss whether lymphoma should be s...

Lymphoma

David G. Maloney, MD, PhD, on Lymphomas: Treatment With CAR T Cells

David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses the efficacy of chimeric antigen receptor (CAR) T cells for lymphoma and their toxicity.

Leukemia
Lymphoma

Susan M. O’Brien, MD, on ALL/Lymphoma: Upfront and Salvage Treatments in Older Patients

Susan M. O’Brien, MD, of the University of California, Irvine, discusses the challenges of treating older patients with acute lymphoblastic leukemia and lymphoma, and the positive res...

Lymphoma

Julie M. Vose, MD, MBA, on Highlights of Pan Pacific Lymphoma 2016

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses the key presentations at the 2016 Pan Pacific Lymphoma Conference.

Advertisement

Advertisement



Advertisement